PAPERS Influenceoforalmagnesiumsupplementationoncardiacevents amongsurvivorsofanacutemyocardialinfarction AndersMGall0e,HenrikSRasmussen,LarsNJ0rgensen,PeterAurup,StenBalsl0v, CristinaCintin,NielsGraudal,PeterMcNair Abstract Objective-Toinvestigatetheeffectoflongterm oralmagnesiumtreatmentonincidenceofcardiac eventsamongsurvivorsofanacutemyocardial infarction.Design-Doubleblind,placebocontrolled parallelstudyinwhichpatientswererandomisedto treatmentorplacebo.Setting-Twocoronarycareunitsandcorres- pondingoutpatientclinics.Subject-468survivorsofanacutemyocardial infarction(289menand178women)aged31-92.Interventions-Onetabletof15mmolmagnesium hydroxideorplacebodailyforoneyear.Mainoutcomemeasures-Incidencesofreinfarc- tion,suddendeath,andcoronaryarterybypass graftinginoneyear.
Results-Therewasnosignificantdifference betweentreatmentandplacebogroupsintheincid- enceofeachofthethreecardiacevents,butwhen theeventswerecombinedanddropoutswere excludedfromcalculationstherewasasignificantly higherincidenceofeventsinthetreatmentgroup (56/167v33/153;relativerisk1.55(95%confidence interval107to225);p=002).Whenthetimingof eventswasincorporatedbymeansofaKaplan- Meierplotthetreatmentgroupshowedasignific- antlyhigherincidenceofeventswhetherdropouts wereincludedorexcluded(p<0025). Conclusion-Longtermoraltreatmentwith15 mmolmagnesiumdailydoesnotreducetheincid- enceofcardiaceventsinsurvivorsofanacute myocardialinfarctionand,indeed,seemstoincrease theriskofdevelopingacardiacevent.Consequently, thistreatmentcannotberecommendedassecondary prophylaxisforsuchpatients.
Introduction Severalstudieshaveshownthatintravenous infusionofmagnesiumintheacutephaseofamyo- cardialinfarctionresultsinasignificantreductionin mortalityandintheincidenceofseriousarrhythmias.' Inourstudyofintravenousmagnesiumtreatment acutemortalitywas19%inagroupgivenplacebo comparedwith7%inagroupgivenmagnesium,and theincidenceofarrhythmiasrequiringtreatmentin thetwogroupswas47%and21%respectively.2 Magnesiuminfusionalsoseemedtoreducethenumber ofverifiedacutemyocardialinfarctionsfrom54%to 41%,indicatingthatmagnesiumprotectedagainstthe developmentofanacutemyocardialinfarctiontosome extent2'orevenreducedthesizeoftheinfarction.5The mechanismsofactionareunknown,butmanypatients withchronicischaemicheartdisease,particularly thosetreatedwithdiureticsordigoxin,become deficientinmagnesium.*'Ithasbeensuggestedthat thismagnesiumdeficiencypredisposespatientstosuddencardiacdeath,10reinfarction,andotherserious cardiacevents."1 Inviewoftheshorttermeffectsofintravenous magnesiumonpatientswithacutemyocardialinfarc- tion,itislogicaltoinvestigatewhetherlongterm treatmentwithmagnesiummayextendthesebenefits intotheperiodaftertheacutephaseofamyocardial infarction,especiallyifmagnesiumdeficiencyisa predisposingfactor.Thepresentstudywasdesignedto evaluatewhethersuchlongtermtreatmentwithoral magnesiumwascapableofreducingtheincidenceof seriouscardiacevents.
Patientsandmethods During18monthspatientsadmittedtothecoronary careunitsoftwouniversityhospitalsinCopenhagen wereincludedinthestudyiftheyhadsurvivedanacute myocardialinfarction,gaveinformedconsent,and escapedtheexclusioncriteriaofsecondorthirddegree atrioventricularorsinoatrialblockadeoraserum creatinineconcentrationabove0-200mmol/l.Before beingdischargedthesepatientswererandomly assignedtooneoftwostudygroups(magnesium treatmentorplacebo)bymeansofasinglesequenceof computergeneratedrandomnumbers.Thetabletsused inthestudy(preparedbyGunnarKjemsChemistry, Copenhagen)wereallsimilarinappearanceandtaste andeithercontained15mmolmagnesiumhydroxide (MABLET)each,equaltotherecommendeddaily dietaryallowanceofmagnesium,'2orwerecomposed ofstarch(placebo).Bygivingadoseofmagnesium equaltotherecommendeddailydietaryallowance inadditiontotheusualdietwehopedthatany magnesiumdeficiencywouldbecorrectedand prevented.Thebioavailabilityofthemagnesium hydroxidehadbeenevaluatedinanotherstudy: urinaryexcretionofmagnesiumhadbeenalmost doubledcomparedwithplacebo.'3 Thepatientswereaskedtostarttreatment,one tabletaday,ontheirfirstdayathomeandtocometo theoutpatientclinicforexaminationat13,26,and52 weeksafterrandomisation.Patientswhodidnotattend wererecalled,andonlythosewhoignoredthisrecallor whoaskedtowithdrawfromthestudywereclassedas dropouts.Oneachvisittotheclinicthepatientswere givenanewbottleoftablets,andtheiroldbottleswere collected.
InDenmarkthetwoprincipaldiagnosesresponsible forapatient'sadmissiontohospitalarereportedtoa centralregisterofhealth.Suddendeathsoccurring outsidehospitalarerecordedinthesameregister.We searchedthisregisterfordetailsofhospitaladmissions andsuddendeathsamongtheparticipatingpatients. Whennecessary,weobtainedcaserecordsfromother hospitalsanddeathcertificatesfromthenationalboard ofhealth.Onlycasesofsuddendeath,verifieddiag- nosesofreinfarction,orcoronaryarterybypassopera- BMJVoLUME3074SEPTEMBER1993DepartmentofMedicineP, BispebjergHospital,2400 Copenhagen,Denmark AndersMGalloe,registrar LarsNJorgensen,registrar StenBalslov,registrar NielsGraudal,registrar DepartmentofMedicineA, HvidovreHospital,2650 Hvidovre,Denmark HenrikSRasmussen, registrar PeterAurup,registrar CristinaCintin,registrar DepartmentofClinical Chemistry,Hvidovre Hospital PeterMcNair,consultant Correspondenceto: DrAMGalloe,Viggo Rothesvejl,2920 Charlottenlund, DK-Denmark.
BMg1993;307:585-7 585 tionswereacceptedascardiacevents.Deathinhospital duetoreinfarctionwasclassifiedasreinfarction.Ifa patienthadmorethanonecardiaceventonlythefirst eventwasincludedinthestatisticalanalysis.Thusthe threeendpointmeasurementswerefullyindependent. Theseeventswereclassifiedbeforethepatients'treat- mentswererevealed.Serumconcentrationsofsodium, potassium,calcium,creatinine,albumin,magnesium, andphosphateweremeasuredinpatients'blood samplestakenbeforerandomisationtothestudyand 13,26,and52weeksafterrandomisation.Thestudy wasapprovedbytheregionalethicscommitteeandby theDanishNationalBoardofHealth.
Calculationsofsamplesizeshadindicatedthat600 patientswouldbesufficienttodetectadecreaseinthe incidenceofcardiaceventsfrom16%to8%withalevel ofsignificanceat005andapowerof0-80.Thetrial wasgiven18monthstoaccomplishthis.Eventually, only502patientswererecruited,buttheperiodof recruitmentcouldnotbeextendedbecausethepartici- patingdepartmentshadagreedtojoinaninternational multicentrestudyincludingthesamecategoryof patients.Consequentlythepowerofthestudywas reducedto075.Theresultswereanalysedbothonan TABLEI-Baselinecharacteristicsof468survivorsofanacute myocardialinfarctionwhowererandomisedtooralmagnesium treatmentorplacebo.Valuesaremeans(standarddeviations)unless statedotherwise TreatmentgroupPlacebogroup Age(years) 67-3(10-5)67-8(11-1) Agerange(years) 32-2-87-931-2-92-2 Noofmen:women 146:88143:90 Bloodpressure(mmHg): Systolic 124(21)124(22) Diastolic 71(13)72(12) Heatrate(beats/min) 81(17)86(14) Weight(kg) 74(15)72(15)Serumconcentrations(mmol/l):Magnesium 0-85(0-10)0-84(0-11) Calcium 2-38(0-16)2-38(0-15) Potassium 3-95(0-43)3-96(0-49) Sodium 140(4)140(4) Creatinine 0-112(0-027)0-121(0-029) Albumin 529(54)519(61) Phosphate 1-14(0-17)1-12(0-15) TABLEiI-Numbersofcardiaceventsanddropoutsamongsurvivors ofanacutemyocardialinfarctionwhowererandomisedtooral magnesiumtreatmentorplacebo TreatmentgroupPlacebogroup (n-251)(n-251) Beforedischargefromhospital Died 98 Withdrewfromstudy 37 Losttofollowup 43 Remainder 235233 By13weeksafterrandomisation Cardiacevents: Reinfarction 1915 Coronaryarterybypass 1I Suddendeath 117 Dropouts: Deathnotduetocardiacevent33 Non-attendance 4058 Remainder 161149 By26weeksafterrandomisation Cardiacevents: Reinfarction 71 Coronaryarterybypass 00 Suddendeath 22 Dropouts: Deathnotduetocardiacevent21 Non-attendance 129 Remainder 138136 By52weeksafterrandomisation Cardiacevents: Reinfarction 107 Coronaryarterybypass 30 Suddendeath 30 Dropouts: Deathnotduetocardiacevent30 Non-attendance 89 Remainder 111120TABLEm-Incidenceofcardiaceventsamongsurvivorsofanacute myocardialinfarctionwhowererandomisedtooralmagnesium treatmentorplacebo No(0/%)ofcardiacevents RelativeriskpValue TreatmentPlacebo(95%confidence(Fisher's groupgroupinterval)exacttest Includingdropouts Noofsubjects235233 Cardiacevents*:58(247)41(17-6)1-40(0-98to200)0-08 Reinfarction37(15-7)27(11-6)1-36(0-86to2-16)0-23 Coronary bypass5(2-1)1(0-4)4-79(0-60to38-30)0-22 Suddendeath16(6-8)13(5-6)1-22(0-60to2-47)0-70 Excludingdropouts Noofsubjects167153 Cardiacevents:56(33-5)33(21-6)1-55(1-07to2.25)0-02 Reinfarction36(21-6)23(15-0)1-43(0-89to2-31)0-15 Coronary bypass4(2-4)1(0-4)3-54(0-42to29-55)0-37 Suddendeath16(9-6)9(5-9)1-63(0-74to2-25)0-30 *Including10dropoutswhoseoutcomesweretracedincentralregisterof health.
intentiontotreatbasis-includingeventsfordrop outs-andafterexclusionofeventsfordropoutsas censoredobservations.Theresultswerecomparedby meansofaKaplan-Meierplotandalogranktest.'4The relativerisksofeachofthethreecardiaceventsandof anyeventwerecalculatedandwerecomparedby meansof95%confidenceintervalsandFisher'stestof exactprobability. Results TableIshowsthepatients'baselinecharacteristics.Therewerenosignificantchangesintheresultsofany ofthebloodtestsmeasuredat13,26,and52weeks afterrandomisation.Themean(SD)serummagnesium concentrationsofthetreatmentgroupandplacebo groupwerenotsignificantlydifferentatbaseline(0-85 (010)v0-84(011)mmol/l)orat13,26,or52weeks afterrandomisation(0-86(011)v0-82(0-10),0-86 (009)v0-84(0-09),and0-85(0410)v0-86(009) mmol/l)althoughthedifferenceat13weekswas borderlinesignificant(p=008).Sixpatientsinthe placebogroupandfivepatientsinthetreatmentgroup hadserummagnesiumconcentrationsbelowthe normalrangelimitof070mmol/l.
TableIIshowstheoccurrenceofcardiaceventsand ofpatientsdroppingoutduringthestudy.Eight patientsinthetreatmentgroupandfourintheplacebo groupdroppedoutbecauseofdeathsnotdueto myocardialinfarction.Theremainingdropoutsfailed toappearintheoutpatientclinicandeitherignored theirrecallorinformedusthattheywishedtowith- draw.Thefateofalldropouts,however,wasascer- tainedfromthecentralregisterofhealthdescribed above. TableIIIshowstheincidenceofcardiaceventsinthe twogroups,bothincludingandexcludingdropouts.
Therewasnosignificantdifferencebetweenthegroups intheincidenceofeachofthethreecardiacevents,but whentheeventswereassessedtogetheranddropouts wereexcludedtherewasasignificantlyhigherincid- enceofeventsinthetreatmentgroup(relativerisk1-55 (95%confidenceinterval107to225)).Aswellas analysingthetotalnumberofeventsinoneyear,we includedthetimingoftheeventsbymeansofa Kaplan-Meierplotandevaluatedthesignificancelevel byalogranktest."4Therewasnosignificantdifference intheincidenceofreinfarctionwhetheronanintention totreatbasis(p>005)orafterexcludingdropouts (p>01).Whensuddendeathsandreinfarctionswere pooled,however,thetreatmentgroupshoweda significantlyhigherincidencethantheplacebogroup onanintentiontotreatbasis(p<005)andafter excludingdropouts(p<005).Whenallthreecardiac BMJVOLUME3074SEPTEMBER1993 586 O20- -s-r 10 ~~5-Treatmentin5 Eol '013263952 Timeafterstartof treatment(weeks) Cumulativeincidenceofcardiac eventsovertimeamongsurivors ofanacutemyocardialinfarction whowererandomisedtooral magnesiumtreatmentorplacebo.
(Incidencecalculatedonan intentiontotreatbasis)eventswerepooledthesignificancewasincreasedwith bothinclusionandexclusionofdropouts(p<0025). Thefigureshowstherelationbetweenthedurationof treatmentandtheaccumulatingnumberofcardiac eventsinthetwogroupsonanintentiontotreatbasis.
Discussion Patientswithacutemyocardialinfarctionoftenhave magnesiumdeficiency~"1anddevelopanadditional hypomagnesaemiaduringtheacutephaseofthe infarct."5'9Acutetreatmentwithintravenous magnesiumnotonlypreventsthetransienthypo- magnesaemiabutinducesahypermagnesaemia, increasingtheserummagnesiumconcentrationby30- 100%."9"0Hence,thebeneficialeffectofintravenous magnesiumtreatmentmaybeascribedtohyper- magnesiaemiaratherthanthecorrectionofhypo- magnesaemia.Ourprotocoloftreatmentwithoral magnesiumsupplementswasnotexpectedtoinduce significantchangesinserummagnesiumconcentra- tions:thetreatmenthadpreviouslybeenshownto nearlydoubletheurinaryexcretionofmagnesiumbut didnotinducechangesinserummagnesiumconcen- tration.'3Inaccordancewiththiswecouldnotdetecta significantincreaseinserummagnesium.
Wefoundnobeneficialeffectofmagnesiumsupple- mentationascomparedwithplacebo,and,surpris- ingly,placeboseemedsuperiortomagnesium:when evaluatedonanintentiontotreatbasisthetreatment grouphad37%morecardiaceventsthantheplacebo group,andwhendropoutswereexcludedthetreat- mentgrouphad55%moreevents.Whenthetiming oftheeventswasincludedthesignificancelevel increased.Themagnesiumtreatment'slackofabene- ficialeffectcouldbeascribedtoaninsufficientdosage orinsufficientbioavailability.Ifso,theincreased incidenceofeventsinthetreatmentgroupcouldbean Clinicalimplications *Manypatientswithchronicischaemicheart diseasebecomedeficientinmagnesium,andthis isthoughttopredisposethemtoseriouscardiac events *Intravenousinfusionofmagnesiuminthe acutephaseofamyocardialinfarctionsignifi- cantlyreducesmortality *Westudiedtheeffectsoflongtermperoral treatmentwithmagnesiumonpatientswhohad survivedanacutemyocardialinfarction *Afteroneyeartheincidenceofcardiacevents was55%higherinthegrouptreatedwith magnesiumcomparedwithcontrols *Peroraltreatmentwithmagnesiumcannotbe recommendedforpatientswhohavesurvivedan acutemyocardialinfarctionexampleofthetypeIstatisticalerror.Sincemag- nesiumtreatmentwassignificantlymoreharmfulthan placebo,however,theriskofatypeIerrorislessthan 005,andthereisnoriskofatypeIIerror.Thismeans thereisalsoaverylowrisk(<00001)ofcommittinga typeIIIerror-ofnotdetectingthatmagnesium supplementationshouldsignificantlyreducetheinci- denceofcardiaceventscomparedwithplacebo.
Ifthedifferenceintheincidenceofeventsbetween thetwogroupswascausedbythetreatmentthen asufficientamountofmagnesiummusthavebeen absorbedtoproducethateffect.Consequently,itis hardtobelievethatalargerdoseofmagnesiumcould haveproducedaneffectintheoppositedirection.It willbeinterestingtolearnfromfuturestudieswhether thepresentstudyisthefirsttodetectpotentialharm fromoralmagnesiumtreatmentorwhetheritisan exampleofatypeIerror. 1TeoKK,YusufS,CollinsR,HeldPH,Peto.Effectsofintravenous magnesiuminsuspectedmyocardialinfarction:overviewofrandomised trials.BM3'1991;303:1499-503.2RasmussenHS,McNairP,BackerV,NorregardP,Lindeneg0,BalslovS.Intravenousmagnesiuminacutemyocardialinfarction.Lancet1986;i: 234-6.3RasmussenHS,McNairP.Magnesiuminfusioninacutemyocardial infarction.Lancet1986;i:551-2.4RasmussenHS,GronbzkM,BalslovS,CintinC,NorregArdP,McNairP.Oneyeardeathratein270patientswithsuspectedacutemyocardial infarctioninitiallytreatedwithintravenousmagnesiumorplacebo.Clin Cardiol1988;11:377-81.
5MortonBC,NairRC,SmithFM,McKibbonTG,PoznanskiWJ.Magnesium therapyinacutemyocardialinfarction:adouble-blindstudy.Magnesium 1984;3:346-52. 6UrmP,JacobE.Magnesiumdeficiencyinpatientsonlongtermdiuretic treatnentforheartfailure.BMJ1972;iii:620-2.7DycknerT,WebsterPO.Intracellularmagnesiumlossafterdiureticadminis- tration.Drugs1984;28(suppl1):161-6.8RyzenE,ElkayamU,RudeRK.Lowbloodmononuclearcellmagnesiumin intensivecareunitpatients.AmHearty1986;111:475-80.9RasmussenHS,McNairP,GoransonL,BalslovS,LarsenOG,AurupP.Magnesiumdeficiencyinpatientswithischemicheartdisease,withan withoutacutemyocardialinfarction,uncoveredbyintravenousloadingtest.ArchInternMed1988;148:329-32.10AlturaBM,AlturaBT.Magnesiumionsandcontractionofvascularsmooth muscles:relationshiptosomevasculardiseases.FedProc1981;40:2672-9.11AlturaBM,AlturaBT,CarellaA,TurlapatyPD.Hypomagnesemiaand vascoconstriction:possiblerelationshiptoetiologyofsuddendeath, ischaemicheartdiseaseandhypertensivevasculardisease.Artery1981;9: 212-31.
12GanongWF.Reviewofmedicalphysiology.8thed.LosAlto,California:Lange MedicalPublications,1977:232. 13RudnictiM,FrolichA,Fisher-RasmussenW.Magnesiumsupplements inpregnancy-inducedhypertension:effectsofmatemalandneonatal magnesiumandcalciumhomeostasis.MinerElectrolyteMetab1991;17:399- 403.14MatthewsDE,FarewellVT.Usingandunderstandingmedicalstatistics.2ndrev ed.London:Karger,1988:79,178.15AbrahamAS,EylathU,WeinsteinM,CzaczkesE.Serummagnesiumlevelsin patientswithacutemyocardialinfarction.NEnglJMed1977;296:862-3.16PetersenB,ChristiansenC,TransbolI.Bloodmineralsincardiacemergencies.DanMedBull1978;25:116-8.17FlinkEB,BrickJE,ShaneSRAlterationsoflongchainfreefattyacidsand magnesiumconcentrationsinacutemyocardialinfarctions.ArchInternMed 1981;141:441-3.18RectorWG,DeWoodMA,WilliamsRV,SullivanJF.Serummagnesiumand copperlevelsinacutemyocardialinfarction.AmJTMedSci1981;281:25-9.
19RasmussenHS,AurupP,HojbjergS,JensenEK,McNairP.Transient hypomagnesemianotinducedbyrenalmagnesiumlossinpatientswith acutemyocardialinfarction.ArchInternMed1986;146:872-4. 20WoodsKL,FletcherS,RoffeC,HaiderY.Intravenousmagnesiumsulphate insuspectedacutemyocardialinfarction:resultsofthesecondLeicester intravenousmagnesiuminterventiontrial(LLMIT-2).Lancet1992;339: 1553-8.(Accepted15June1993) BMJVOLUME3074SEPlTEMBER1993 587
